Home - Products - GPCR/G Protein - Glucagon Receptor - Glucagon-like peptide 1 (1-37), human

Glucagon-like peptide 1 (1-37), human

CAS No. 87805-34-3

Glucagon-like peptide 1 (1-37), human( HuGLP-1 )

Catalog No. M29847 CAS No. 87805-34-3

Glucagon-like peptide 1 (1-37), human is a highly potent agonist of the GLP-1 receptor.Pancreatic hormone synthesized by post-translational processing of proglucagon. Unlike truncated forms of GLP-1, it has no effect on food intake in rats and does not enhance pancreatic insulin secretion.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote

Biological Information

  • Product Name
    Glucagon-like peptide 1 (1-37), human
  • Note
    Research use only, not for human use.
  • Brief Description
    Glucagon-like peptide 1 (1-37), human is a highly potent agonist of the GLP-1 receptor.Pancreatic hormone synthesized by post-translational processing of proglucagon. Unlike truncated forms of GLP-1, it has no effect on food intake in rats and does not enhance pancreatic insulin secretion.
  • Description
    Glucagon-like peptide 1 (1-37), human is a highly potent agonist of the GLP-1 receptor.Pancreatic hormone synthesized by post-translational processing of proglucagon. Unlike truncated forms of GLP-1, it has no effect on food intake in rats and does not enhance pancreatic insulin secretion.(In Vitro):Glucagon-like peptide-1 (GLP-1) is produced by the posttranslational processing of proglucagon and acts as a regulator of various homeostatic events. GLP-1(1-37) is more stable than GLP-1(7-37), with 94.7% of the initial amount of peptide left after a 4h exposure to mouse serum. GLP-1(1-37) is confirmed to be a highly potent agonist of the GLP-1 receptor (GLP-1R) by measuring the expression of the luciferase reporter gene expression in transiently transfected human embryonic kidney (HEK293) cells.(In Vivo):GLP-1(1–37) decreased glycemic excursion in a dose-dependent. The administration of GLP-1(1–37) or GLP-1(7–37) markedly decrease blood glucose levels at 15 min and 30 min compared with the control group.
  • In Vitro
    Glucagon-like peptide-1 (GLP-1) is produced by the posttranslational processing of proglucagon and acts as a regulator of various homeostatic events. GLP-1(1-37) is more stable than GLP-1(7-37), with 94.7% of the initial amount of peptide left after a 4h exposure to mouse serum. GLP-1(1-37) is confirmed to be a highly potent agonist of the GLP-1 receptor (GLP-1R) by measuring the expression of the luciferase reporter gene expression in transiently transfected human embryonic kidney (HEK293) cells.
  • In Vivo
    GLP-1(1–37) decreased glycemic excursion in a dose-dependent. The administration of GLP-1(1–37) or GLP-1(7–37) markedly decrease blood glucose levels at 15 min and 30 min compared with the control group.
  • Synonyms
    HuGLP-1
  • Pathway
    GPCR/G Protein
  • Target
    Glucagon Receptor
  • Recptor
    GLP-1 receptor
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    87805-34-3
  • Formula Weight
    4169.48
  • Molecular Formula
    C186H275N51O59
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    Sequence:His-Asp-Glu-Phe-Glu-Arg-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

Zhao L, et al. Glucagon-like peptide-1(1-37) can enhance blood glucose homeostasis in mice. Regul Pept. 2012 Oct 10;178(1-3):1-5.
molnova catalog
related products
  • GLP-1R modulator L7-...

    GLP-1R modulator L7-028 is a variant that enhances affinity for GLP-1 and (cAMP) signaling.

  • MK-0893

    A potent, selective, reversible and competitive antagonist of glucagon receptor with high binding affinity (IC(=50=6.6 nM) and functional cAMP activity (IC50=15.7 nM).

  • Retatrutide

    Retatrutide (LY3437943) is a triple agonist of the glucagon receptor, glucose-dependent insulinotropic polypeptide receptor, and glucagon-like peptide-1 receptor (GLP-1R), and inhibits GCGR, GIPR, and GLP-1R.Retatrutide can be used to study obesity.